Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.59 |
| ▸ | TERT | O14746 | 2/20 | 0.50 |
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682186 | 0.90 | DTYMK (0.54) | DTYMKTERTF2 | |
| SCHEMBL26189441 | 0.88 | DTYMK (0.59) | DTYMKTERTTK1POLB | |
| SCHEMBL14064192 | 0.86 | POLB (0.55) | POLB | |
| SCHEMBL27062466 | 0.85 | DTYMK (0.60) | DTYMKTERTTK1POLBF2 | |
| SCHEMBL21299317 | 0.85 | DTYMK (0.63) | DTYMKTERTTK1POLBF2 | |
| SCHEMBL29306797 | 0.84 | DTYMK (0.64) | DTYMKTERTTK1F2 | |
| SCHEMBL25896349 | 0.84 | DTYMK (0.64) | DTYMKTERTTK1F2 | |
| SCHEMBL17589251 | 0.84 | TERT (0.49) | DTYMKTERTTK1POLBF2 | |
| SCHEMBL17589254 | 0.84 | TERT (0.48) | DTYMKTERTPOLBF2 | |
| SCHEMBL29607650 | 0.83 | DTYMK (0.75) | DTYMKTERTTK1POLBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110280963-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ISIS PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280963-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | EIF5B, EIF2B5, EIF4B | DTYMK 465/4885TERT 2974/4885TK1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.